stockportfolio.pro
Stocks / ANRO vs AVTX
ANRO vs AVTX
Alto Neuroscience, Inc. and Avalo Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alto Neuroscience, Inc. (ANRO) | Avalo Therapeutics, Inc. (AVTX) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $0 | $59,000 |
| Net income (latest FY) | $-63.24M | $-78.26M |
| Revenue growth (5y CAGR) | — | -61.2% |
| Net margin | — | -132642.4% |
| Return on equity | -41.8% | -94.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANRO — free Open AVTX — freeFrequently asked questions
Which is bigger, ANRO or AVTX?
Alto Neuroscience, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, ANRO or AVTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.